Conquering CML The Breakthrough Paradigm Change of Treatment-free Remission - 4

Welcome to the MolecularMD eBook

Knocking on the Front Door of

Precision Medicine
Great advancements
have
been made in
the Precision
Medicine movement, which are a result of
gaining a deeper biological understanding
of disease through the use of powerful life
science tools. Achieving insights like understanding a therapeutic's mode of action,
or identifying a cancer's vulnerability are
proving to be transformative to healthcare.
Biomarkers have and continue to play a
key role in the successes for targeted drugs
and immunotherapies. In fact, PhRMA
states that 73% of the cancer medicines
in the pipeline are likely to be personalized medicines, and that over the next five
years there will be a 69% increase in the
development of these types of therapies.
Biomarkers have become the new norm

A Clinical OMICs eBook

and they are integral to a drug development program. Today, the use of a biomarker for patient selection improves the
probability three-fold for approval of a
drug candidate.
At MolecularMD, it is our belief that
diagnostics aid in clinical decision making,
and our role is to assist clients in de-risking
their development programs. With more
than ten years of experience, MolecularMD
has built out the capabilities, and knowledge, to serve as a trusted advisor to our
clients in the biopharma industry.
One of MolecularMD's demonstrated
successes has been in the area of Chronic
Myeloid Leukemia (CML) and a novel treatment approach which is now being used
by progressive clinicians. In this publication you will find many interesting details
about the MRDx® BCR-ABL Test being

deployed as a Companion Diagnostic.
MolecularMD's MRDx® Test is used in conjunction with Tasigna® to identify, initiate,
and monitor Treatment-free Remission,
which enables patients to safely go off
the drug. This is personalized medicine
in its truest sense, providing patients
with the right drug at the right time.

n the spirit of advancing a dialogue,
I would like to invite you to provide
feedback on the articles in this eBook.
Our success in Precision
Medicine relies on a
collaborative exchange between
-Fritz Eibel
the research,
Senior VP, Marketing
feibel@molecularmd.com
clinical, pharma
and regulatory
communities.

www.clinicalomics.com

http://www.clinicalomics.com

Conquering CML The Breakthrough Paradigm Change of Treatment-free Remission

Table of Contents for the Digital Edition of Conquering CML The Breakthrough Paradigm Change of Treatment-free Remission